Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
In vitro studies demonstrate that treatment with the peptide BPC-157 increases GHR mRNA and protein levels in a dose- and time-dependent manner, enhancing the fibroblasts responsiveness to growth hormone and promoting cell proliferation essential for tendon healing
No pharmacokinetic interaction: Tirzepatide slows gastric emptying, but TB-500 is administered by injection and enters the bloodstream directly, bypassing the GI tract entirely
Faster tendon healing in animal models Journal of Applied Physiology, 2011 Knee pain relief in human patients Journal of Orthopaedic Surgery and Research, 2021 Safety profile across soft tissue indications Current Pharmaceutical Design, 2019 The statements on this page have not been evaluated by the Food and Drug Administration
Timmermans notes that the patent for BPC-157 expired long ago, which means that no company presently has a clear profit motive to spend millions to fund human studies
Tirzepatide is a 39amino acid dual incretin receptor agonist that activates both GLP1 and GIP receptors, enhancing glucosedependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite [1] [2]
US$ 25.49
US$ 27.60
US$ 22.65
US$ 21.19
US$ 29.52
